Ye P - Search Results

1

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.

Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S. Moriarty PM, et al. Among authors: ye p. J Clin Lipidol. 2014 Nov-Dec;8(6):568-575. doi: 10.1016/j.jacl.2014.09.002. Epub 2014 Sep 16. J Clin Lipidol. 2014. PMID: 25499939 Clinical Trial.

2

[The beneficial effects of xuezhikang on top of extended-released nifedipine in hypertensive patients without severe hyperlipidemia].

Wu CE, Ye P. Wu CE, et al. Among authors: ye p. Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Oct;34(10):886-9. Zhonghua Xin Xue Guan Bing Za Zhi. 2006. PMID: 17217712 Clinical Trial. Chinese.

3

[The effect of Xuezhikang on ventricular diastolic function in hypertension].

Ye P, Wu CE, Li H, Zhi G. Ye P, et al. Zhonghua Nei Ke Za Zhi. 2006 Oct;45(10):811-4. Zhonghua Nei Ke Za Zhi. 2006. PMID: 17217744 Clinical Trial. Chinese.

4

Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.

Ye P, Lu ZL, Du BM, Chen Z, Wu YF, Yu XH, Zhao YC; CCSPS Investigators. Ye P, et al. J Am Geriatr Soc. 2007 Jul;55(7):1015-22. doi: 10.1111/j.1532-5415.2007.01230.x. J Am Geriatr Soc. 2007. PMID: 17608873 Clinical Trial.

5

Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension.

Ye P, Wu CE, Sheng L, Li H. Ye P, et al. J Altern Complement Med. 2009 Jul;15(7):719-25. doi: 10.1089/acm.2008.0599. J Altern Complement Med. 2009. PMID: 19552598 Clinical Trial.

6

Xuezhikang therapy increases miR-33 expression in patients with low HDL-C levels.

Cao R, Bai Y, Sun L, Zheng J, Zu M, Du G, Ye P. Cao R, et al. Among authors: ye p. Dis Markers. 2014;2014:781780. doi: 10.1155/2014/781780. Epub 2014 Jan 23. Dis Markers. 2014. PMID: 24591767 Free PMC article.

7

Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).

Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, Li Z, Wei Y, Ambegaonakr BM, Hu D; DYSIS-China Study Investigators. Zhao S, et al. Among authors: ye p. Atherosclerosis. 2014 Aug;235(2):463-9. doi: 10.1016/j.atherosclerosis.2014.05.916. Epub 2014 Jun 5. Atherosclerosis. 2014. PMID: 24950001

8

Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).

Wang F, Ye P, Hu D, Min Y, Zhao S, Wang Y, Mu Y, Yan X, Li Z, Wei Y, Li J; DYSIS-China Study Investigators. Wang F, et al. Among authors: ye p. Atherosclerosis. 2014 Nov;237(1):99-105. doi: 10.1016/j.atherosclerosis.2014.08.023. Epub 2014 Sep 1. Atherosclerosis. 2014. PMID: 25238215

9

Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China.

Wei Y, Guo H, The E, Che W, Shen J, Hou L, Zhao S, Ye P, Li G, Wang D, Jie Q, Hu D. Wei Y, et al. Among authors: ye p. Int J Cardiol. 2015 Mar 1;182:469-75. doi: 10.1016/j.ijcard.2015.01.024. Epub 2015 Jan 7. Int J Cardiol. 2015. PMID: 25612824

10

Analysis of Lipoprotein Subfractions in Chinese Han Patients with Stable Coronary Artery Disease.

Xu RX, Zhang Y, Ye P, Chen H, Li YF, Hua Q, Guo YL, Li XL, Li S, Dong Q, Liu G, Li JJ. Xu RX, et al. Among authors: ye p. Heart Lung Circ. 2015 Dec;24(12):1203-10. doi: 10.1016/j.hlc.2015.05.002. Epub 2015 May 30. Heart Lung Circ. 2015. PMID: 26105990 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,928 results

Search Page